Recursion Pharmaceuticals reports Q3 EPS (36c), consensus (38c)

Reports Q3 revenue $5.2M, consensus $19.36M. Cash, cash equivalents and restricted cash were $667.1M as of September 30, compared to $603.0M as of December 31, 2024. “Recursion continues to deliver on our internal pipeline, our strategic partnerships and the continued building and refinement of the Recursion OS. On the partnership front, we are proud to announce that with the option of our second neuro map in the Roche and Genentech collaboration, we’ve achieved over $500M in upfront and milestone payments from our partners to date as we continue to deliver novel insights and advance programs for some of the toughest disease areas,” said Chris Gibson, Co-Founder and CEO of Recursion. “This is only the beginning of the returns we expect to see on the investment in our platform. With a strong cash runway through the end of 2027, we look forward to delivering on our pipeline and proving that building an end-to-end AI-enabled platform-combining massive proprietary datasets with industry-leading supercomputing capabilities and sophisticated AI models-is the critical infrastructure we need to realize real change in our industry.”